Article Text

Download PDFPDF

O3 Physician experience influences glucocorticoid prescribing patterns in systemic lupus erythematosus (SLE): results from the LUPHPOS survey
  1. Cristiana Sieiro Santos1,
  2. Sarah Dyball2,
  3. Kunal Chandwar3,
  4. Elisabetta Chessa4 and
  5. Marta Mosca5
  1. 1Rheumatology Dept., Complejo Asistencial Universitario de León, León, Spain
  2. 2Centre for Musculoskeletal Research, the University of Manchester, UK
  3. 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, India
  4. 4Rheumatology Unit, AOU Cagliari, Cagliari, Italy
  5. 5Rheumatology Unit, Dept. of Clinical and Experimental Medicine, Pisa, Italy

Abstract

Objectives To explore the variations in glucocorticoid prescribing practices according to the physician’s years of experience in managing SLE.

Methods The LUPHPOS (LUpus PHysician’ Perspective On glucocorticoidS) study is an online cross-sectional self-reported survey on the physician’s perspective of glucocorticoids in the management of SLE, disseminated between April-August 2023. We have compared responses between practitioners with ≤10 years (shorter experience, SE) and those with >10 years of experience (longer experience, LE).

Results A weight-based regimen for prescribing glucocorticoids was preferred by both groups, table 1. No differences in glucocorticoid prescribing practices were found in mild and moderate flares. The most common dose was 0.10 mg/kg/day or 5–10 mg/day in mild flares, and 0.25–0.3 mg/kg/day or 15–20 mg/day in moderate flares. In severe flares, pulse therapy was used more often by SE physicians (79% vs 65%, p=0.01). The commonest dose was 500 mg/day for both groups over 3 days. SE physicians more frequently prescribed pulse doses >500 mg/day (41% vs 29%, p=0.02), and pulses for >3 days (24% vs 5%, p<0.001).

The most frequently reported target dose for tapering steroids was ≤5mg/day in both groups, however LE physicians targeted 0 mg/day more frequently (22% vs 13%, p=0.04). Steroid withdrawal >12 months after achieving remission/LLDAS was preferred by both groups.

Both groups agreed that current disease activity, and type of organ involvement, were the main deciding factors for selecting steroid dose. LE physicians rated comorbidities as their third key driver (39%), whereas SE physicians ranked the course of the disease (44%). There was agreement that infection, cushingoid features, and osteoporosis were the most influencing factors for withdrawing steroids.

Conclusions The years of experience influence the use of glucocorticoid therapy in severe flare management, tapering protocols, and steroid withdrawal. These differences underscore the need for wide-reaching dissemination and implementation strategies to ensure the adoption of evidence-based care practices across all levels of clinical experience.

Abstract O3 Table 1

Glucocorticoid prescribing practices in SE and LE physicians

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.